$70.95
+4.26 (+6.39%)
Last updated: Apr 16, 2026 02:30
Fundamentals Overview
Arrowhead Pharmaceuticals, Inc. is near the high of its 52-week range with premium valuation, showing strong upward momentum today.
Valuation premium
Profitability
Risk (Beta)
1.27 — higher vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B- · 3M vs S&P 500: +6.9% · 3M vs Healthcare sector: +13.7%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B-. Current institutional positions: Buy: 17, Equal Weight: 3, Neutral: 3, Outperform: 4, Overweight: 3.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-103.79; current price is $70.95. That’s a -246.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 49.36 |
| PEG (TTM) | 0.38 |
| P/B (TTM) | 17.48 |
| P/S (TTM) | 9.11 |
| P/FCF (TTM) | 30.85 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.38 |
| Quick Ratio (TTM) | 3.38 |
| Cash Ratio (TTM) | 0.58 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 18.54% |
| Gross margin (TTM) | 97.7% |
| Operating margin (TTM) | 27.55% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ARWR.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-25 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-10 |
| B. Riley Securities | maintain | Buy | Buy | 2026-01-22 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-01-21 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-01-13 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-01-07 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-01-07 |
| Chardan Capital | maintain | Buy | Buy | 2026-01-07 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-12-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-12-11 |
| B of A Securities | maintain | Buy | Buy | 2025-12-09 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-12-02 |
| B of A Securities | maintain | Buy | Buy | 2025-12-01 |
| Chardan Capital | maintain | Buy | Buy | 2025-12-01 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-26 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-11-20 |
| Chardan Capital | maintain | Buy | Buy | 2025-11-19 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-19 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-11-19 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-02 |
| Chardan Capital | maintain | Buy | Buy | 2025-08-11 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-05-20 |
| Citigroup | maintain | Neutral | Neutral | 2025-05-13 |
| Chardan Capital | maintain | Buy | Buy | 2025-05-13 |
| B. Riley Securities | maintain | Buy | Buy | 2025-02-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-02-12 |
| RBC Capital | maintain | Outperform | Outperform | 2025-02-11 |